Armata Pharmaceuticals, Inc. ARMP Stock Forecast
AI-powered price prediction and analysis for Armata Pharmaceuticals, Inc. · Alpha · vs marketSwitch to Total
See ARMP's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. (ARMP) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry.
Latest News
Where ARMP sits on the market map
Biological Products, (No Diagnostic Substances) Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| ARMP Armata Pharmaceuticals, Inc. | ▲ | $112M | – |
| AMGN Amgen Inc | ▼ | $234.65B | 27.0x |
| GILD Gilead Sciences, Inc. | ▲ | $195.13B | – |
| MRNA Moderna, Inc. | ▲ | $94.42B | – |
| ARGX Argenx Se | ▼ | $52.37B | 22.2x |
| RVMD Revolution Medicines, Inc. | ▲ | $41.48B | – |
| BIIB Biogen Inc. | ▼ | $34.53B | 25.3x |
| BNTX Biontech Se | ▲ | $22.81B | 2.3x |
| EXEL Exelixis, Inc. | ▶ | $15.57B | 18.1x |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.92B | 19.8x |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.79B | 27.9x |
| TECH Bio-Techne Corp | ▼ | $11.37B | 62.5x |
| IBRX Immunitybio, Inc. | ▲ | $10.60B | – |
| RGEN Repligen Corp | ▶ | $10.06B | 258.2x |
| PCVX Vaxcyte, Inc. | ▲ | $10.05B | – |
| QGEN Qiagen N.V. | ▶ | $9.88B | 32.3x |
| KRYS Krystal Biotech, Inc. | ▶ | $9.77B | 41.4x |
| TWST Twist Bioscience Corp | ▲ | $9.29B | – |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.99B | – |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.67B | – |
| IMVT Immunovant, Inc. | ▲ | $5.68B | – |
| KOD Kodiak Sciences Inc. | ▲ | $5.54B | – |
| CGON Cg Oncology, Inc. | ▲ | $5.48B | – |
| CRSP Crispr Therapeutics Ag | ▲ | $4.98B | – |
| SRRK Scholar Rock Holding Corp | ▲ | $4.82B | – |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.08B | – |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.74B | – |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.17B | – |
| DNLI Denali Therapeutics Inc. | ▼ | $2.93B | – |
| BEAM Beam Therapeutics Inc. | ▲ | $2.55B | 98.9x |
| LIFE Atyr Pharma Inc | ▲ | $2.45B | – |
| ADMA Adma Biologics, Inc. | ▼ | $2.40B | 17.3x |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.25B | – |
| NVAX Novavax Inc | ▲ | $2.08B | – |
| VCEL Vericel Corp | ▲ | $2.06B | 85.1x |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.05B | – |
| ALVO Alvotech | ▲ | $1.90B | – |
| MESO Mesoblast Ltd | ▶ | $1.79B | – |
| VIR Vir Biotechnology, Inc. | ▲ | $1.76B | – |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.53B | – |
| COAG Hemab Therapeutics Holdings, Inc. | ▶ | $1.52B | – |
| IMCR Immunocore Holdings Plc | ▶ | $1.52B | – |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.22B | – |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.14B | – |
| VOR Vor Biopharma Inc. | ▶ | $1.11B | – |
| REPL Replimune Group, Inc. | ▲ | $1.07B | – |
| JATT Zura Bio Ltd | ▶ | $994M | – |
| VALN Valneva Se | ▼ | $965M | – |
| IMTX Immatics N.V. | ▲ | $957M | – |
| MGTX Meiragtx Holdings Plc | ▼ | $950M | 12.8x |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $901M | – |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $863M | – |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $798M | – |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M | – |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $711M | – |
| SANA Sana Biotechnology, Inc. | ▲ | $698M | – |
| CADL Candel Therapeutics, Inc. | ▲ | $682M | – |
| AURA Aura Biosciences, Inc. | ▲ | $657M | – |
| SLDB Solid Biosciences Inc. | ▲ | $586M | – |
| PRME Prime Medicine, Inc. | ▲ | $568M | – |
FAQ
Is Armata Pharmaceuticals, Inc. a good stock to buy?
Our AI analyzes Armata Pharmaceuticals, Inc. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Armata Pharmaceuticals, Inc. predictions?
For ARMP, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 12.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 24.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Armata Pharmaceuticals, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Armata Pharmaceuticals, Inc.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.